Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised Clinical Trial Comparing Early Medication Change (EMC) Strategy With Treatment as Usual (TAU) in Patients With Major Depressive Disorder - the EMC Trial.

Next Previous
Trial Profile

Randomised Clinical Trial Comparing Early Medication Change (EMC) Strategy With Treatment as Usual (TAU) in Patients With Major Depressive Disorder - the EMC Trial.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Nov 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Escitalopram (Primary) ; Lithium (Primary) ; Venlafaxine (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms EMC

Most Recent Events

  • 16 Nov 2020 Results published in the Journal of Clinical Psychopharmacology
  • 04 Dec 2012 Planned end date changed from 1 Sep 2012 to 1 Sep 2014 as reported by ClinicalTrials.gov.
  • 20 Mar 2012 Planned number of patients changed from 640 to 940 as reported by EudraCT.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top